Lexeo Therapeutics, Inc.
LXEO
$4.84
-$0.12-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -9.56% | -17.47% | -13.89% | 3.16% | 27.57% |
| Gross Profit | 9.56% | 17.47% | 13.89% | -3.16% | -27.57% |
| SG&A Expenses | -42.73% | -13.01% | 43.52% | 61.68% | 104.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.93% | -15.91% | 3.30% | 21.60% | 50.35% |
| Operating Income | 22.93% | 15.91% | -3.30% | -21.60% | -50.35% |
| Income Before Tax | 23.57% | 19.95% | -1.66% | -21.21% | -47.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.57% | 19.95% | -1.66% | -21.21% | -47.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.57% | 19.95% | -1.66% | -21.21% | -47.86% |
| EBIT | 22.93% | 15.91% | -3.30% | -21.60% | -50.35% |
| EBITDA | 23.05% | 15.98% | -3.36% | -21.79% | -50.76% |
| EPS Basic | 64.50% | 56.00% | 29.16% | 14.86% | 77.73% |
| Normalized Basic EPS | 65.35% | 53.69% | 26.73% | 12.46% | 77.20% |
| EPS Diluted | 64.50% | 56.00% | 29.16% | 14.86% | 77.73% |
| Normalized Diluted EPS | 65.35% | 53.69% | 26.73% | 12.46% | 77.20% |
| Average Basic Shares Outstanding | 112.95% | 98.17% | 68.36% | 54.54% | 80.69% |
| Average Diluted Shares Outstanding | 112.95% | 98.17% | 68.36% | 54.54% | 80.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |